BNTC

Benitec Biopharma Ltd (BNTC) | Rumor.io

Benitec Biopharma

BNTC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,147

Bullish sentiment (50-day avg)100%

Price to earnings ratio-9.55

Market capitalization349.5M

Earnings per share-0.98

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-37.9M

Social

What share of all stock conversation is about BNTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% new	0% 0

Mar 9

Benitec Biopharma announced positive interim phase 1b/2a results for its gene therapy BB-301, showing durable improvements for low dose treatment and promising results for high dose treatment in patients with oculopharyngeal muscular dystrophy (OPMD).
The company reported that low dose BB-301 treatment showed sustained improvements at 12 and 24 months, while high dose treatment showed deeper improvements at 3 months.
BB-301 has shown potential in treating OPMD with moderate dysphagia, with Benitec Biopharma planning to add more high dose patients and focus on sustaining the treatment's effects in future studies.

Generated by AI

Sentiment

Of the messages about BNTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	96.7% -0.86
Bearish	—	—	0%	3.3% +0.86

Bullish· Apr 18

Benitec Biopharma's stock has shown significant momentum, with a 26.58% increase, and has been identified as one of the most impressive stocks in the moment.
The company's stock has rallied 11.2% and is heading for $8, with a low short interest of 0.5% and a float of 2.3M shares.
Benitec Biopharma's stock is expected to reach $10 or higher, with some analysts predicting a 100%+ increase in value, driven by positive news and a strong run past the $6 mark.

Bearish· Aug 9

Benitec Biopharma Inc. ($BNTC) may face negative consequences from a past public offering that affected common shareholders.
The company's recent jumbo offering and 1-for-17 reverse split may be indicative of a plan to "rob" investors.
Benitec Biopharma's focus on burning through cash, combined with a limited market for its treatment of only 15,000 people, may lead to a decline in the company's value.

Generated by AI

Topics

Of the messages about BNTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	76.92%	87.1%
Analysts	0%	0%	23.08%	12.9%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Announcements· Apr 18

Benitec Biopharma Inc. raised $40.0 million through an oversubscribed private placement financing, selling 5,749,152 shares of common stock at $4.80 per share.
The company announced positive interim clinical trial data for its first OPMD subject treated with BB-301 in a Phase 1b/2a study, a promising development for its gene therapy platform.
Benitec Biopharma's oversubscribed private placement financing was seen as a vote of confidence in the company's gene therapy advancements, leading to a significant increase in investor confidence.

Controversies· Jun 25

A cybersecurity lawsuit in New York threatens to impact Carnival Corporation's Q2 performance, and the ticker $BNTC is mentioned alongside $CCL, $USAK, and $PPCB.
The lawsuit is a major concern for investors, and the mention of $BNTC suggests that Benitec Biopharma Inc. may be indirectly affected by the controversy.
The repeated mention of $BNTC alongside $CCL, $USAK, and $PPCB in posts about the cybersecurity lawsuit implies that the company is being associated with the controversy, although the exact nature of its involvement is unclear.

Technical Analysis· Jun 24

$BNTC is completing an inverse head and shoulders pattern on the minute chart, potentially leading to an uptrend back to $1.80-$2.00.
The stock is consolidating and dips are being bought, with new highs of day being made, and a retest of $1.85 expected.
$BNTC has held its 20 MA and is showing higher lows, with a potential breakout from an ascending triangle and a retest of $1.64 expected.

Generated by AI

Community

Of the messages about BNTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80%	28.57%	43.69%
Newcomers	100%	20%	71.43%	56.31%

Regulars· Apr 18

Benitec Biopharma reports positive interim clinical trial data for the first OPMD subject treated with BB-301 in Phase 1b/2a study, with a 24% pre-market increase and a super low float of 2.5M shares.
The company announces an oversubscribed private placement financing of $40.0 million, which is expected to fuel groundbreaking gene therapy advancements and rejuvenate investor confidence.
Benitec Biopharma's stock is up 17.47% in the pre-market, with a momentum continuing and a short interest of 0.5%, after the company raises $40 million in the oversubscribed private placement financing.

Newcomers· Apr 18

Newcomers are focusing on the positive interim clinical trial data for Benitec Biopharma's BB-301 treatment for Oculopharyngeal Muscular Dystrophy (OPMD), which has shown exciting improvements in swallowing function.
The private placement financing of $40.0 million from the sale of 5,749,152 shares of Benitec Biopharma's common stock at $4.80 per share is being discussed as a significant development for the company.
The halted trading of Benitec Biopharma's stock for the second time in a day is being noted, with users directing interested parties to additional information and news about the company.

Generated by AI

News

H.C. Wainwright reiterates Benitec Biopharma stock rating at buy

1d agoInvesting.com

Benitec Biopharma appoints Ernst & Young as new auditor, replaces Baker Tilly

5d agoInvesting.com

Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating

15d agoYahoo Finance

Citizens reiterates Benitec Biopharma stock rating ahead of FDA talks

15d agoInvesting.com

Benitec completes patient follow-up, plans pivotal trial in 2027

15d agoInvesting.com

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberAdditional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking

15d agoYahoo Finance

Also Discussed

Investors talking about BNTC also mention

#	Name	Attention
1	Pulmatrix Inc.PULM	0%0
2	XMax Inc.NVFY	0%0
3	Jiayin Group Inc. ADRJFIN	0%new
4	EpicQuest Education Group International LimitedEEIQ	0%0
5	YTEN - Yield10 Bioscience, Inc.	——
6	Cellectar Biosciences, Inc.CLRB	0%new
7	BLPH - Bellerophon Therapeutics, Inc.	——
8	XTL Biopharmaceuticals Ltd. - ADRXTLB	0%0
9	IVAC - Intevac, Inc.	——
10	TKAT - Takung Art Co., Ltd.	——

Benitec Biopharma Ltd

Healthcare
Biotechnology

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform. The company combines RNA interference with gene therapy to create treatments designed to silence disease-causing genes while also delivering functional gene replacement in a single administration. Its current work centers on ddRNAi-based therapeutics for chronic and life-threatening conditions, with a particular emphasis on rare genetic disorders such as oculopharyngeal muscular dystrophy. Benitec Biopharma’s pipeline reflects a precision medicine approach aimed at addressing unmet needs in genetic disease through targeted, durable molecular intervention. Headquartered in Hayward, California, Benitec Biopharma Inc. operates in the biotechnology and gene therapy sectors, where it contributes to the development of advanced platform-based therapies for difficult-to-treat human diseases.

Website

Location

3940 Trust Way

Hayward, CA, 94545

United States

Social

What share of all stock conversation is about BNTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% new	0% 0

Mar 9

Benitec Biopharma announced positive interim phase 1b/2a results for its gene therapy BB-301, showing durable improvements for low dose treatment and promising results for high dose treatment in patients with oculopharyngeal muscular dystrophy (OPMD).
The company reported that low dose BB-301 treatment showed sustained improvements at 12 and 24 months, while high dose treatment showed deeper improvements at 3 months.
BB-301 has shown potential in treating OPMD with moderate dysphagia, with Benitec Biopharma planning to add more high dose patients and focus on sustaining the treatment's effects in future studies.

Generated by AI

Sentiment

Of the messages about BNTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	96.7% -0.86
Bearish	—	—	0%	3.3% +0.86

Bullish· Apr 18

Benitec Biopharma's stock has shown significant momentum, with a 26.58% increase, and has been identified as one of the most impressive stocks in the moment.
The company's stock has rallied 11.2% and is heading for $8, with a low short interest of 0.5% and a float of 2.3M shares.
Benitec Biopharma's stock is expected to reach $10 or higher, with some analysts predicting a 100%+ increase in value, driven by positive news and a strong run past the $6 mark.

Bearish· Aug 9

Benitec Biopharma Inc. ($BNTC) may face negative consequences from a past public offering that affected common shareholders.
The company's recent jumbo offering and 1-for-17 reverse split may be indicative of a plan to "rob" investors.
Benitec Biopharma's focus on burning through cash, combined with a limited market for its treatment of only 15,000 people, may lead to a decline in the company's value.

Generated by AI

Topics

Of the messages about BNTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	76.92%	87.1%
Analysts	0%	0%	23.08%	12.9%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Announcements· Apr 18

Benitec Biopharma Inc. raised $40.0 million through an oversubscribed private placement financing, selling 5,749,152 shares of common stock at $4.80 per share.
The company announced positive interim clinical trial data for its first OPMD subject treated with BB-301 in a Phase 1b/2a study, a promising development for its gene therapy platform.
Benitec Biopharma's oversubscribed private placement financing was seen as a vote of confidence in the company's gene therapy advancements, leading to a significant increase in investor confidence.

Controversies· Jun 25

A cybersecurity lawsuit in New York threatens to impact Carnival Corporation's Q2 performance, and the ticker $BNTC is mentioned alongside $CCL, $USAK, and $PPCB.
The lawsuit is a major concern for investors, and the mention of $BNTC suggests that Benitec Biopharma Inc. may be indirectly affected by the controversy.
The repeated mention of $BNTC alongside $CCL, $USAK, and $PPCB in posts about the cybersecurity lawsuit implies that the company is being associated with the controversy, although the exact nature of its involvement is unclear.

Technical Analysis· Jun 24

$BNTC is completing an inverse head and shoulders pattern on the minute chart, potentially leading to an uptrend back to $1.80-$2.00.
The stock is consolidating and dips are being bought, with new highs of day being made, and a retest of $1.85 expected.
$BNTC has held its 20 MA and is showing higher lows, with a potential breakout from an ascending triangle and a retest of $1.64 expected.

Generated by AI

Community

Of the messages about BNTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80%	28.57%	43.69%
Newcomers	100%	20%	71.43%	56.31%

Regulars· Apr 18

Benitec Biopharma reports positive interim clinical trial data for the first OPMD subject treated with BB-301 in Phase 1b/2a study, with a 24% pre-market increase and a super low float of 2.5M shares.
The company announces an oversubscribed private placement financing of $40.0 million, which is expected to fuel groundbreaking gene therapy advancements and rejuvenate investor confidence.
Benitec Biopharma's stock is up 17.47% in the pre-market, with a momentum continuing and a short interest of 0.5%, after the company raises $40 million in the oversubscribed private placement financing.

Newcomers· Apr 18

Newcomers are focusing on the positive interim clinical trial data for Benitec Biopharma's BB-301 treatment for Oculopharyngeal Muscular Dystrophy (OPMD), which has shown exciting improvements in swallowing function.
The private placement financing of $40.0 million from the sale of 5,749,152 shares of Benitec Biopharma's common stock at $4.80 per share is being discussed as a significant development for the company.
The halted trading of Benitec Biopharma's stock for the second time in a day is being noted, with users directing interested parties to additional information and news about the company.

Generated by AI

Benitec Biopharma

Social

Mar 9

Bullish· Apr 18

Bearish· Aug 9

Announcements· Apr 18

Controversies· Jun 25

Technical Analysis· Jun 24

Regulars· Apr 18

Newcomers· Apr 18

H.C. Wainwright reiterates Benitec Biopharma stock rating at buy

Benitec Biopharma appoints Ernst & Young as new auditor, replaces Baker Tilly

Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating

Citizens reiterates Benitec Biopharma stock rating ahead of FDA talks

Benitec completes patient follow-up, plans pivotal trial in 2027

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Also Discussed

Benitec Biopharma Ltd

Company Information

Location

H.C. Wainwright reiterates Benitec Biopharma stock rating at buy

Benitec Biopharma appoints Ernst & Young as new auditor, replaces Baker Tilly

Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating

Citizens reiterates Benitec Biopharma stock rating ahead of FDA talks

Benitec completes patient follow-up, plans pivotal trial in 2027

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Also Discussed

Social

Mar 9

Bullish· Apr 18

Bearish· Aug 9

Announcements· Apr 18

Controversies· Jun 25

Technical Analysis· Jun 24

Regulars· Apr 18

Newcomers· Apr 18